Mary Hebert

Professor, Department of Pharmacy, Director, UW; Obstetric-Fetal Pharmacology Research Unit; Adjunct Professor, Department of Obstetrics and Gynecology (OBGYN), UW Medicine

Department of Pharmacy, OPRU , Pharmacy Faculty

Telephone: (206) 616-5016

Fax: (206) 543-3835


Office Location: H375-R Box 357630 1959 NE Pacific St Seattle, WA 98195-7630

Expertise: Pregnancy and Fetal Pharmacology, Transplantation


  • PharmD, University of California, San Francisco

Research Interests

  • Clinical pharmacology in pregnancy and lactation
  • Pharmacokinetics/pharmacodynamics of immune modulators

Courses Taught

  • Pharm 562: Pharmacotherapeutics III


Mary F. Hebert, FCCP, is professor of pharmacy and adjunct professor of OBGYN, Director of the University of Washington Obstetric-Fetal Pharmacology Research Unit, core member of the UW Center for Ecogenetics and Environmental Health and member of the UW Institute of Translational Health Sciences. She is a fellow of the American College of Clinical Pharmacy. Dr. Hebert received her PharmD degree in 1987, completed a clinical pharmacy residency in 1988 and Fellowship in 1990 at the University of California, San Francisco. Hebert joined the UW faculty in 1996 after serving on the clinical faculty at the University of California, San Francisco for six years.

She has 26 years of experience conducting clinical pharmacokinetic and pharmacodynamic trials resulting in 82 publications. She has been an invited speaker at many national and international conferences. Her research focuses on the pharmacokinetics and pharmacodynamics of immune modulators in solid organ transplantation and the clinical pharmacology of medications in pregnancy and lactation. Her current work in obstetric-fetal pharmacology focuses on the mechanistic basis for clinical pharmacology changes in medications of therapeutic value during pregnancy.

Selected Publications

Caritis SN, Hebert MF. A pharmacological approach to the use of glyburide in pregnancy. Obstet Gynecol. 2013 Jun;121(6):1309-12.

Hebert MF, Zheng S, Hays K, Shen DD, Davis CL, Umans JG, Miodovnik M, Thummel KE, Easterling TR. Interpreting Tacrolimus Concentrations During Pregnancy and Postpartum. Transplantation. 2013 Apr 15;95(7):908-15.

Haas DM, Quinney SK, Clay J, Renbarger JL, Hebert MF, Clark S, Umans J, Caritis SN, for the Obstetric-fetal Pharmacology Research Units Network. Nifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolytic. Am J Perinatol. 2013 Apr;30(4):275-81.

Hays KE, Ryu RJ, Swisher EM, Reed E, McManus T, Rybeck B, Petros WP, Hebert MF. Duration of cisplatin excretion in breast milk. J Hum Lact. 2013 Mar 14. [Epub ahead of print]

Zheng S, Tasnif Y, Hebert MF, Davis CL, Shitara Y, Calamia JC, Lin Y, Shen DD, Thummel KE. CYP3A5 gene variation influences cyclosporine A metabolite formation and renal cyclosporine disposition. Transplantation. 2013 Mar 27;95(6):821-7.

Shuster DL, Bammler TK, Beyer RP, MacDonad JW, Tsai JM, Farin FM, Hebert MF, Thummel KE, Mao Q. Gestational age-dependent changes in gene expression of metabolic enzymes and transporters in pregnant mice. Drug Metab Dispos. 2013 Feb;41(2):332-42.

Zheng S, Easterling TR, Umans JG, Miodovnik M, Calamia JC, Thummel KE, Shen DD, Davis CL, Hebert MF. Pharmacokinetics of Tacrolimus During Pregnancy. Ther Drug Monit. 2012 Dec;34(6):660-70.

Van Hasselt JGC, Andrew MA, Hebert MF, Tarning J, Vicini P, Mattison DR. The Status of Pharmacometrics in Pregnancy: Highlights from the 3rd American Conference on Pharmacometrics.Br J Clin Pharmacol. 2012 Dec;74(6):932-9.

Caritis SN, Sharma S, Venkataramanan R, Hankins GD, Miodovnik M, Hebert MF, Umans JG, Benedetti T, Mattison D, Zajicek A, Fischer D, Jackson A. Pharmacology and Placental Transport of 17-Hydroxyprogesterone Caproate in Singleton GestationAm J Obstet Gynecol. 2012 Nov;207(5):398.e1-8.

Quinney SK, Mahamed AN, Hebert MF, Haas DM, Clark S, Umans JG, Caritis SN, Li L. A semi-mechanistic metabolism model of CYP3A substrates in pregnancy: predicting changes in midazolam and nifedipine pharmacokinetics. CPT Pharmacometrics Syst Pharmacol. 2012 Sep 26;1:e2.

Wang Z, Lin YS, Zheng XE, Senn T, Hashizume T, Scian M, Dickmann LJ, Nelson SD, Baillie TA, Hebert MF, Blough D, Davis CL, Thummel KE. An inducible cytochrome P450 3A4-dependent vitamin D catabolic pathway. Mol Pharmacol. 2012 Apr;81(4):498-509.

Wang Z, Senn T, Kalhorn T, Zheng XE, Zheng S, Davis CL, Hebert MF, Lin YS, Thummel KE. Simultaneous measurement of plasma vitamin D(3) metabolites, including 4‘_,25-dihydroxyvitamin D(3), using liquid chromatography-tandem mass spectrometry.Anal Biochem. 2011 Nov 1;418(1):126-33.

Haas DM, Gallauresi B, Shields K, Zeitlin D, Clark SM, Hebert MF, Ren Z, Nallani SC, Meslin EM, Feibus KB, Koren G, Goebel WS, Easterling T, Denne SC, Flockhard DA, Renbarger JL. Pharmacotherapy and pregnancy: highlights from the third international conference for individualized pharmacotherapy in pregnancy. Clin Transl Sci. 2011 Jun;4(3):204-9.

Beigi RH, Han K, Venkataramanan R, Hankins GD, Clark S, Hebert MF, Easterling T, Zajicek A, Ren Z, Mattison DR, Caritis SN. Pharmacokinetics of Oseltamivir among pregnant and non-pregnant women. Am J Obstet Gynecol. 2011 Jun;204(6 Suppl 1):S84-8.